pHA-eIF4E Citations (8)
Originally described in: ISG15 modification of the eIF4E cognate 4EHP enhances cap structure-binding activity of 4EHP.Okumura F, Zou W, Zhang DE Genes Dev. 2007 Feb 1. 21(3):255-60. PubMed Journal
Articles Citing pHA-eIF4E
| Articles |
|---|
PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis.
Ilic N, Utermark T, Widlund HR, Roberts TM.
Proc Natl Acad Sci U S A. 2011 Sep 13;108(37):E699-708. Epub 2011 Aug 29.
PubMed
Associated Plasmids |
| The PP242 mammalian target of rapamycin (mTOR) inhibitor activates extracellular signal-regulated kinase (ERK) in multiple myeloma cells via a target of rapamycin complex 1 (TORC1)/eukaryotic translation initiation factor 4E (eIF-4E)/RAF pathway and activation is a mechanism of resistance. Hoang B, Benavides A, Shi Y, Yang Y, Frost P, Gera J, Lichtenstein A. J Biol Chem. 2012 Jun 22;287(26):21796-805. doi: 10.1074/jbc.M111.304626. Epub 2012 May 3. PubMed |
| Mechanistic target of rapamycin (mTOR) dependent regulation of thioredoxin interacting protein (TXNIP) transcription in hypoxia. Wong RW, Hagen T. Biochem Biophys Res Commun. 2013 Mar 29;433(1):40-6. doi: 10.1016/j.bbrc.2013.02.070. Epub 2013 Feb 26. PubMed |
| MNK1-induced eIF-4E phosphorylation in myeloma cells: a pathway mediating IL-6-induced expansion and expression of genes involved in metabolic and proteotoxic responses. Shi Y, Frost P, Hoang B, Yang Y, Bardeleben C, Gera J, Lichtenstein A. PLoS One. 2014 Apr 8;9(4):e94011. doi: 10.1371/journal.pone.0094011. eCollection 2014. PubMed |
| Cotargeting MNK and MEK kinases induces the regression of NF1-mutant cancers. Lock R, Ingraham R, Maertens O, Miller AL, Weledji N, Legius E, Konicek BM, Yan SC, Graff JR, Cichowski K. J Clin Invest. 2016 Jun 1;126(6):2181-90. doi: 10.1172/JCI85183. Epub 2016 May 9. PubMed |
| MNK Inhibition Sensitizes KRAS-Mutant Colorectal Cancer to mTORC1 Inhibition by Reducing eIF4E Phosphorylation and c-MYC Expression. Knight JRP, Alexandrou C, Skalka GL, Vlahov N, Pennel K, Officer L, Teodosio A, Kanellos G, Gay DM, May-Wilson S, Smith EM, Najumudeen AK, Gilroy K, Ridgway RA, Flanagan DJ, Smith RCL, McDonald L, MacKay C, Cheasty A, McArthur K, Stanway E, Leach JD, Jackstadt R, Waldron JA, Campbell AD, Vlachogiannis G, Valeri N, Haigis KM, Sonenberg N, Proud CG, Jones NP, Swarbrick ME, McKinnon HJ, Faller WJ, Le Quesne J, Edwards J, Willis AE, Bushell M, Sansom OJ. Cancer Discov. 2021 May;11(5):1228-1247. doi: 10.1158/2159-8290.CD-20-0652. Epub 2020 Dec 16. PubMed |
| mTORC1 induces eukaryotic translation initiation factor 4E interaction with TOS-S6 kinase 1 and its activation. Majeed ST, Batool A, Majeed R, Bhat NN, Zargar MA, Andrabi KI. Cell Cycle. 2021 May;20(9):839-854. doi: 10.1080/15384101.2021.1901038. Epub 2021 May 3. PubMed |
| The Akt-mTOR Pathway Drives Myelin Sheath Growth by Regulating Cap-Dependent Translation. Fedder-Semmes KN, Appel B. J Neurosci. 2021 Oct 13;41(41):8532-8544. doi: 10.1523/JNEUROSCI.0783-21.2021. Epub 2021 Sep 2. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.